|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACSS1 |
Gene summary for ACSS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACSS1 | Gene ID | 84532 |
| Gene name | acyl-CoA synthetase short chain family member 1 | |
| Gene Alias | ACAS2L | |
| Cytomap | 20p11.21 | |
| Gene Type | protein-coding | GO ID | GO:0006066 | UniProtAcc | Q9NUB1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84532 | ACSS1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.88e-03 | 4.36e-01 | -0.0811 |
| 84532 | ACSS1 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.08e-03 | 3.59e-01 | -0.1088 |
| 84532 | ACSS1 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.21e-06 | 3.78e-01 | -0.1464 |
| 84532 | ACSS1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 8.58e-12 | 6.36e-01 | -0.059 |
| 84532 | ACSS1 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.59e-02 | 3.08e-01 | 0.096 |
| 84532 | ACSS1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.83e-09 | 4.50e-01 | 0.0674 |
| 84532 | ACSS1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.17e-15 | 7.74e-01 | 0.281 |
| 84532 | ACSS1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.98e-07 | 4.83e-01 | 0.3859 |
| 84532 | ACSS1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.55e-23 | 6.76e-01 | 0.3005 |
| 84532 | ACSS1 | LZE2T | Human | Esophagus | ESCC | 2.67e-07 | 5.54e-01 | 0.082 |
| 84532 | ACSS1 | LZE24T | Human | Esophagus | ESCC | 1.25e-13 | 1.92e-01 | 0.0596 |
| 84532 | ACSS1 | LZE21T | Human | Esophagus | ESCC | 2.34e-02 | 1.04e-01 | 0.0655 |
| 84532 | ACSS1 | P1T-E | Human | Esophagus | ESCC | 4.62e-02 | 1.11e-01 | 0.0875 |
| 84532 | ACSS1 | P2T-E | Human | Esophagus | ESCC | 4.78e-31 | 5.10e-01 | 0.1177 |
| 84532 | ACSS1 | P4T-E | Human | Esophagus | ESCC | 3.59e-15 | 2.13e-01 | 0.1323 |
| 84532 | ACSS1 | P5T-E | Human | Esophagus | ESCC | 7.59e-06 | 2.27e-02 | 0.1327 |
| 84532 | ACSS1 | P8T-E | Human | Esophagus | ESCC | 2.94e-05 | 1.08e-01 | 0.0889 |
| 84532 | ACSS1 | P9T-E | Human | Esophagus | ESCC | 2.67e-07 | 2.30e-01 | 0.1131 |
| 84532 | ACSS1 | P10T-E | Human | Esophagus | ESCC | 5.66e-59 | 1.02e+00 | 0.116 |
| 84532 | ACSS1 | P11T-E | Human | Esophagus | ESCC | 1.73e-04 | 1.24e-01 | 0.1426 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001969319 | Oral cavity | OSCC | ribose phosphate metabolic process | 199/7305 | 396/18723 | 2.97e-06 | 3.64e-05 | 199 |
| GO:00060667 | Oral cavity | OSCC | alcohol metabolic process | 179/7305 | 353/18723 | 4.54e-06 | 5.21e-05 | 179 |
| GO:000925919 | Oral cavity | OSCC | ribonucleotide metabolic process | 189/7305 | 385/18723 | 3.18e-05 | 2.87e-04 | 189 |
| GO:00442724 | Oral cavity | OSCC | sulfur compound biosynthetic process | 82/7305 | 148/18723 | 3.71e-05 | 3.31e-04 | 82 |
| GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
| GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
| GO:000915020 | Oral cavity | OSCC | purine ribonucleotide metabolic process | 178/7305 | 368/18723 | 1.45e-04 | 1.02e-03 | 178 |
| GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
| GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
| GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
| GO:000616320 | Oral cavity | OSCC | purine nucleotide metabolic process | 188/7305 | 396/18723 | 3.31e-04 | 2.04e-03 | 188 |
| GO:00338663 | Oral cavity | OSCC | nucleoside bisphosphate biosynthetic process | 36/7305 | 60/18723 | 7.94e-04 | 4.27e-03 | 36 |
| GO:00340303 | Oral cavity | OSCC | ribonucleoside bisphosphate biosynthetic process | 36/7305 | 60/18723 | 7.94e-04 | 4.27e-03 | 36 |
| GO:00340333 | Oral cavity | OSCC | purine nucleoside bisphosphate biosynthetic process | 36/7305 | 60/18723 | 7.94e-04 | 4.27e-03 | 36 |
| GO:19012938 | Oral cavity | OSCC | nucleoside phosphate biosynthetic process | 125/7305 | 256/18723 | 8.32e-04 | 4.41e-03 | 125 |
| GO:00091658 | Oral cavity | OSCC | nucleotide biosynthetic process | 124/7305 | 254/18723 | 8.79e-04 | 4.63e-03 | 124 |
| GO:004639017 | Oral cavity | OSCC | ribose phosphate biosynthetic process | 95/7305 | 190/18723 | 1.30e-03 | 6.46e-03 | 95 |
| GO:00353843 | Oral cavity | OSCC | thioester biosynthetic process | 28/7305 | 45/18723 | 1.36e-03 | 6.62e-03 | 28 |
| GO:00716163 | Oral cavity | OSCC | acyl-CoA biosynthetic process | 28/7305 | 45/18723 | 1.36e-03 | 6.62e-03 | 28 |
| GO:00338654 | Oral cavity | OSCC | nucleoside bisphosphate metabolic process | 66/7305 | 128/18723 | 2.58e-03 | 1.13e-02 | 66 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
| hsa00620 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
| hsa00010 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
| hsa00640 | Colorectum | AD | Propanoate metabolism | 18/2092 | 32/8465 | 1.33e-04 | 1.11e-03 | 7.08e-04 | 18 |
| hsa00630 | Colorectum | AD | Glyoxylate and dicarboxylate metabolism | 14/2092 | 30/8465 | 7.25e-03 | 2.97e-02 | 1.89e-02 | 14 |
| hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
| hsa006201 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
| hsa000101 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
| hsa006401 | Colorectum | AD | Propanoate metabolism | 18/2092 | 32/8465 | 1.33e-04 | 1.11e-03 | 7.08e-04 | 18 |
| hsa006301 | Colorectum | AD | Glyoxylate and dicarboxylate metabolism | 14/2092 | 30/8465 | 7.25e-03 | 2.97e-02 | 1.89e-02 | 14 |
| hsa006204 | Colorectum | MSS | Pyruvate metabolism | 24/1875 | 47/8465 | 1.25e-05 | 1.35e-04 | 8.27e-05 | 24 |
| hsa012004 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
| hsa000104 | Colorectum | MSS | Glycolysis / Gluconeogenesis | 28/1875 | 67/8465 | 2.36e-04 | 1.81e-03 | 1.11e-03 | 28 |
| hsa006404 | Colorectum | MSS | Propanoate metabolism | 15/1875 | 32/8465 | 1.68e-03 | 9.05e-03 | 5.55e-03 | 15 |
| hsa006205 | Colorectum | MSS | Pyruvate metabolism | 24/1875 | 47/8465 | 1.25e-05 | 1.35e-04 | 8.27e-05 | 24 |
| hsa012005 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
| hsa000105 | Colorectum | MSS | Glycolysis / Gluconeogenesis | 28/1875 | 67/8465 | 2.36e-04 | 1.81e-03 | 1.11e-03 | 28 |
| hsa006405 | Colorectum | MSS | Propanoate metabolism | 15/1875 | 32/8465 | 1.68e-03 | 9.05e-03 | 5.55e-03 | 15 |
| hsa0062023 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
| hsa0062033 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACSS1 | SNV | Missense_Mutation | c.1361C>T | p.Ala454Val | p.A454V | Q9NUB1 | protein_coding | tolerated(0.07) | possibly_damaging(0.72) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ACSS1 | SNV | Missense_Mutation | novel | c.1648N>A | p.Asp550Asn | p.D550N | Q9NUB1 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| ACSS1 | insertion | In_Frame_Ins | novel | c.1646_1647insTATTTACTTAAATGCTCTCTTTAAATTGACGCATTGCAA | p.Met549delinsIleIleTyrLeuAsnAlaLeuPheLysLeuThrHisCysLys | p.M549delinsIIYLNALFKLTHCK | Q9NUB1 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| ACSS1 | SNV | Missense_Mutation | novel | c.1363N>G | p.Pro455Ala | p.P455A | Q9NUB1 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACSS1 | SNV | Missense_Mutation | rs375554533 | c.1406C>T | p.Ala469Val | p.A469V | Q9NUB1 | protein_coding | deleterious(0.01) | probably_damaging(0.914) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ACSS1 | SNV | Missense_Mutation | c.1226N>G | p.Ser409Cys | p.S409C | Q9NUB1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ACSS1 | SNV | Missense_Mutation | rs778094981 | c.136N>T | p.Pro46Ser | p.P46S | Q9NUB1 | protein_coding | tolerated(0.08) | benign(0) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACSS1 | SNV | Missense_Mutation | novel | c.1265N>A | p.Cys422Tyr | p.C422Y | Q9NUB1 | protein_coding | tolerated(0.13) | benign(0) | TCGA-VS-A8EJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ACSS1 | SNV | Missense_Mutation | novel | c.1915N>T | p.Arg639Trp | p.R639W | Q9NUB1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACSS1 | SNV | Missense_Mutation | rs371113008 | c.1936N>T | p.Arg646Trp | p.R646W | Q9NUB1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |